In in vivo studies, apatinib successfully inhibited the invasion and migration of osteosarcoma cells through suppression of epithelial–mesenchymal transition (EMT) and inactivation of signal transducer and activator of transcription 3 (STAT3), which is involved in cell growth through downstream signaling molecules (BCL2 (B-cell lymphoma 2) and cyclin D1). This evidence concerns the gene STAT3 and osteosarcoma.